The discovery of HAMLET defines a new class of cancer drugs with broad effects against cancers of different origin and a high degree of selectivity. HAMLET’s aim is to prove the efficacy of HAMLET therapy and to develop drugs that kill tumour cells with greater precision than current drugs.
Hamlet Biopharma originates from a merge of two companies, Hamlet Pharma and SelectImmune Pharma, creating an innovative pharmaceutical company with a broad and strong portfolio of projects for the treatment of cancer and infections. An additional pharmaceutical project with patent rights for the treatment of tuberculosis is also included in the company portfolio.
The two pharmaceutical companies Hamlet Pharma AB and SelectImmune Pharma AB, listed on the Spotlight Stock Market, has per 2023-05-17 been merged to create a powerful pharmaceutical company for drug development for the treatment of cancer and infectious diseases. The merged company, Hamlet Biopharma, holds a portfolio with a total of ten pharmaceutical projects, of which three projects are in phase II, where two of the projects already have positive results in clinical studies. The portfolio includes a total of eleven patent families for cancer, infections and tuberculosis with more than 60 patents. Hamlet Biopharma is now building a focused commercial organization with access to a technology platform and university-based scientist as well as an extensive network of international specialists for drug development and clinical studies. A larger listed company will become more cost-effective and attract talents to the company as well as to the network.
Project |
For treatment |
Phase |
| Alpha 1H Cancer |
Bladder cancer | Phase II clinical trials |
| Alpha 1H Cancer |
Brain tumor | Positive data in animal model, development of technology |
| Hamlet Cancer |
Colon and rectal cancer | Preclinical evaluation |
| Hamlet Cancer |
Oral cavity cancer | Preclinical evaluation |
Project |
For treatment |
Phase |
| IL1-beta receptor antagonist Infections |
Infection and inflammation | Preclinical evaluation Phase II – clinical trials a) Bladder pain syndrome b) Recurrent acute cystitis |
| NK1R receptor antagonist Infections |
Inhibitor of pain and nerve activation | Positive data in animal model, development of technology. Development of substance for clinical studies |
| RNA Pol II inhibitors Infections |
Preventive inflammation inhibitor | Positive data in animal model, development of technology Development of substance for clinical studies |
| RNA Pol II bacteriotherapy Infections |
Prevention of inflammation and treatment of infection | Positive data in animal model, development of technology |
| IRF7 inhibitor, siRNA Infections |
Inhibits severe bacterial infections | Positive data in animal model, development of technology Data to support the development of drugs for clinical studies |
Project |
For treatment |
Phase |
| Project tuberculosis Plectasin Tuberculosis |
Lung tuberculosis | Positive data in animal model, development of technology for drug production |